Recruiting

New Cancer Treatment Compared to Standard Chemotherapy for Ovarian Cancer

Plain-English translation of NCT06828354 on ClinicalTrials.gov ↗ · Source last updated April 2026 · Translation generated June 2026 · How we translate trials

Read our Ovarian Cancer research guide →

Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.

What is this trial?

This trial is testing a new injectable medication called to see if it works better than standard chemotherapy for ovarian cancer that has come back after previous platinum-based treatment. About 300 people will participate, with half receiving the new medication and half receiving chemotherapy chosen by their doctor. The study will measure how well the medication works and how safe it is.

Ovarian cancer that returns after platinum-based chemotherapy is very difficult to treat, and patients need better options. This trial exists to find out whether this medication offers a more effective or better-tolerated alternative to current chemotherapy choices.

Do you qualify?

You likely qualify if…

you have been diagnosed with ovarian, fallopian tube, or primary peritoneal cancer that has returned after platinum-based treatment
you have measurable cancer visible on scans or imaging tests
you are in good enough overall health to tolerate treatment (Eastern Cooperative Group performance status 0 or 1)
you have a life expectancy of at least 12 weeks
you are willing to sign the informed consent form and voluntarily join the study

You likely don't qualify if…

you have untreated or active cancer in your brain or central nervous system that is causing symptoms
you have uncontrolled or severe heart disease or cardiovascular problems
you have an active autoimmune disease or a history of autoimmune disease
you have active hepatitis B, hepatitis C, or tuberculosis
you have a severe infection before starting the study treatment

What participation looks like

If you join this study, you will be randomly assigned to receive either the new injectable medication or standard chemotherapy chosen by your doctor. You will visit the study center regularly for injections, blood tests, and scans to monitor how well the treatment is working and to check for any side effects. The study involves about 300 participants across multiple medical centers.

AI-generated summary from trial data · Jun 6, 2026 · Not medical advice

Trial locations(2 sites)

China

Tongji Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei

Qilu Hospital of Shandong University, Jinan, Shandong